Crossmark

Liraglutide alleviates sepsis-associated encephalopathy via attenuating neuronal damage, glial cell activation and mitochondrial dysfunction in a mouse model of sepsis

Crossref DOI link: https://doi.org/10.1186/s40001-026-03974-0

Published Online: 2026-02-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Xiaoming

Wang, Jun

Zhang, Rongji

He, Haoran

Wang, Linjue

Wang, Yuliang

Yi, Hongyu
License Information

Text and Data Mining valid from 2026-02-01

Version of Record valid from 2026-03-02
More Information

Article History

Received: 8 December 2025

Accepted: 23 January 2026

First Online: 1 February 2026

Declarations

:

: The Scientific Investigation Board of the Chongqing University Cancer Hospital, (Chongqing, China) approved all experiments (No. 2022-X18-19), which were conducted in perfect adherence to the National Institutes of Health’s Guide for the Care and Use of Laboratory Animals Guidelines.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below